NCT06660940View on ClinicalTrials.gov

Clinical Trial of Keluoxin Capsules in the Treatment of Diabetic Kidney Disease with Diabetic Retinopathy

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

460

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Diabetic Kidney DiseaseDiabetic Retinopathy
Interventions
DRUG

Keluoxin Capsules

Treatment period (52 weeks):Keluoxin Capsules, 4 capsules/time, swallow with warm water after meals, 3 times/day

DRUG

Keluoxin Capsule Simulants

Treatment period (52 weeks):Keluoxin Capsule Simulants, 4 capsules/time, swallow with warm water after meals, 3 times/day

DRUG

Irbesartan

"1. Lead-in period (2-4 weeks): Irbesartan 75-300mg/d, QD;~2. Treatment period (52 weeks): Irbesartan 75-300mg/d, QD"

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER

NCT06660940 - Clinical Trial of Keluoxin Capsules in the Treatment of Diabetic Kidney Disease with Diabetic Retinopathy | Biotech Hunter | Biotech Hunter